Advertisement
Advertisement
RARE
Ultragenyx Pharmaceutical Inc.
31.80
USD+0.52
+1.65%
Sep 05, 16:00 UTC -4
Closed
After-Market
31.81
+0.01
+0.04%
Ultragenyx Pharmaceutical Inc. Profile
Info & Links
CEO
Emil D. Kakkis
Headquarters
Novato, CA 94949, UNITED STATES
Industry
Sector
Website
Auditor
Ernst & Young LLP
Share holders
8
Employees
1,294
Ultragenyx Pharmaceutical Inc. Statistics
Valuation Measures
Market Capitalization2
3.07B
Enterprise Value
2.89B
Enterprise Value/EBITDA(ttm)
-6.04
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
85.07%
Operating Margin(ttm)
--
Profit Margin(ttm)
-88.53%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
-271.46%
Return on Assets(ttm)
--
Income Statement
Revenue(ttm)
610.16M
Revenue Per Share(ttm)
6.33
Gross Profit(ttm)
520.58M
EBITDA(ttm)3
-478.35M
Net Income Available to Common(ttm)
-532.93M
Diluted EPS(ttm)
--
Share Statistics
Beta (5Y Monthly)
--
52-Week Change
-43.34%
S&P 500 52-Week Change
17.77%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
96.37M
Dividend Yield
--
Float4
--
% Held by Insiders
--
% Held by Institutions
--
Balance Sheet
Total Cash(mrq)
487.58M
Total Cash Per Share(mrq)
5.06
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
2.45%
Quick Ratio(mrq)
--
Book Value Per Share(mrq)
1.57
Cash Flow
Operating Cash Flow Per Share(ytd)
-2.79
Free Cash Flow(ytd)
-278.53M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement